Work

Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study

Year: 2020

Type: article

Source: Journal of Hepatology

DOI: 10.1016/s0168-8278(20)30759-5

Authors: Michel Ducreux, Andrew Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Ho Yeong Lim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed Kaseb, Daneng Li, Wendy Verret, Zhen Xu, Sairy Hernandez, Juan Liu, Hui Shao, Chen Huang, Ann-LII Cheng, Richard Finn, Peter Galle

Institutions: Institut Gustave Roussy, Massachusetts General Hospital, Center for Cancer Research, PLA Army Engineering University, National Cancer Center Hospital East, New Generation University College, Samsung Medical Center, Kindai University, Russian Cancer Research Center NN Blokhin, Hôpital de la Croix-Rousse, The University of Texas MD Anderson Cancer Center, City of Hope, Roche (China), National Taiwan University, National Taiwan University Hospital, University Medical Center of the Johannes Gutenberg University Mainz

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4239808409

FWCI: 0.123

Cites:

Cited by: 1

Related to: 10